Kornimate/medical-research-clean huggingface dataset:
assessing feasibility of prolonged repetitive near infrared light stimulation in early to mid-stage dementia

Conditions: Mild to Moderate Dementia

Summary: this study will gather data to see if infrared and near infrared light frequency can increase the activity of brain cells and provide support for the cell's ability to repair and protect themselves against further damage.

research suggests that impaired regional cerebral blood flow (rcbf) \[flow of blood in certain parts of the brain\] plays an important role in dementia. infrared and near infrared light frequency has been shown to increase the activity of brain cells and provide support for the cell's ability to repair and protect themselves against further damage. this study will evaluate the effects of repeated brief exposure to near infrared light stimulation twice a day on subjects that have problems such as attention span, working memory, strategies of learning and remembering, planning, organizing, self-monitoring, inhibition and flexible thinking for an 8 week period.

Eligibility criteria:
inclusion criteria: * aged 50-85 years with an independently provided diagnosis of dementia, probable alzheimer's type. * dementia symptoms not greater than early to mid-stage dementia * generally healthy as indicated by recent physical examination within the last 6 months * if labs are available within the last 6 months, renal function, hepatic function, cardiac function should be normal exclusion criteria: * diagnosed actively growing intracranial pathology (tumors etc.) * misusing illegal substances or alcohol * previous history of stroke * history of aggression or violence * history of major psychiatric illness * no underlying cns pathology (confined to tumor, epilepsy only)

Keywords: dementia
nutrition optimalization among pregnant women to improve maternal and neonatal outcome in dki jakarta

Conditions: Pregnancy Complications; Maternal Death; Preeclampsia; Intrauterine Infection; Pregnancy Hemorrhage; Preterm Birth; Neonatal Death; Low; Birthweight, Extremely (999 Grams or Less); Asphyxia Neonatorum; IUGR

Summary: the goal of this monas study is to learn about comprehensive monitoring and nutritional intervention among pregnant women in order to improve maternal and neonatal outcomes. the main questions it aims to answer are: 1. are comprehensive monitoring and nutritional intervention among pregnant women can improve maternal outcomes (maternal death, preterm labour, preeclampsia, intrauterine infection, and bleeding during pregnancy and delivery) compared to standard maternal health services? 2. are comprehensive monitoring and nutritional intervention among pregnant women can improve neonatal outcomes (neonatal death, low birth weight, intrauterine growth restriction, and neonatal asphyxia) compared to standard maternal health services? participants in the intervention group will receive: * fetomaternal ultrasound examination each trimester * complete laboratory examination for nutritional panel (complete blood count with reticulocyte profile and iron profile, vitamin d level, zinc level, fatty acid profile, electrophoresis for thalassemia) as an addition to standard maternal routine laboratory examination * supplements: multivitamin, minerals, vitamin d, fatty acid * intervention regarding any abnormal results of nutritional panel * all standard maternal health services according to indonesian ministry of health protocol participants in the control group will receive: - all standard maternal health services according to indonesian ministry of health protocol


Eligibility criteria:
inclusion criteria: * pregnancy in 1st trimester * gestational age less than 10 weeks * living in jakarta greater area * agree to participate exclusion criteria: * assisted reproductive technology (ivf) * history of polycystic ovary syndrome * history of chronic hypertension * history of diabetes mellitus * history of preeclampsia in the previous pregnancy * had chronic disease: heart disease, autoimmune disease, malignancy, chronic lung disease * planning to have delivery outside jakarta greater area * poor obstetric history (miscarriage/ abortion more than 3 times)
samsung medical center-lymphoma cohort study-ii

Conditions: Lymphoma

Summary: the purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. thus, this study is going to assess factors which may affect the treatment outcome and the risk of treatment-related morbidity. 1.biologic factors associated with the aggressiveness of lymphoma * molecular markers in serum, cytogenetic markers 2.factors associated with the risk of treatment-related morbidity * comorbidity, nutrition status, performance status, quality of life at diagnosis

Eligibility criteria:
inclusion criteria: * patients who were diagnosed as lymphoma * over 19 years old * patients who agreed the enrollment of study * informed consent for sampling exclusion criteria: •patients who do not want to join the study

Keywords: lymphoma prognosis biomarker quality of life
efficacy and safety of dep114 in the treatment of moderate to severe persistent allergic rhinitis in children.

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to evaluate the efficacy and safety of dep114 in the treatment of moderate to severe persistent allergic rhinitis in children aged between 6 and 11 years.

* double-blind, superiority, parallel group trial. * experiment duration: 05 days. * 03 visits (days 0, 5 and 28). * efficacy will be evaluated for persistent allergic rhinitis based on global improvement in nasal symptoms score * adverse events evaluation.

Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree for all the purposes of the test, signing and dating the term of free and informed assent (tale), signed by the free and informed consent form (tcle) by responsible; * age ≥ 6 years and ≤ 11 years on the day of signing the tale and the tcle by the person responsible; * diagnosis of moderate to severe persistent allergic rhinitis (par) according to the criteria of allergic rhinitis and its impact on asthma (aria); * presence of sensitization to aeroallergens confirmed by positive result to the immediate reading skin test (prick test) and/or the presence of specific ige to the test radioallergoabsorbent (rast); * symptom intensity score "nasal obstruction" ≥ 2 points. * total nasal symptoms score (tnss) ≥ 8 points. exclusion criteria: * use of prednisolone or other oral or parenteral corticosteroid in the seven (07) days prior to inclusion; * use of h1 antihistamine, anti-leukotriene and decongestant topic in the seven (07) days prior to inclusion; * use or indication for the use of antibiotics at the screening visit and randomization; * presence of adenoid hypertrophy or anatomical disorders known obstructive disorders (e.g. septal deviation) that may be held responsible for nasal obstruction, at the discretion of the investigator; * diagnosis of severe or uncontrolled asthma; * allergy to desloratadine, prednisolone or any other component of the formulation of investigational products (psis); * presence of systemic fungal infection; * presence of any uncontrolled infection; * presence of any clinical observation finding (evaluation clinical/physical) or laboratory condition that is interpreted by the investigator physician as a risk to participation in the trial clinical or presence of serious uncontrolled disease(s); * participants who are pregnant or breastfeeding; * participation in clinical trial protocols in the last 12 (twelve) months (cns resolution 251, of august 7, 1997, item iii, subitem j), unless the investigator believes that there may be direct benefit to the participant.
registry of pre-mixed solutions in critically ill patients on the continuous renal replacement therapy

Conditions: Renal Insufficiency

Summary: this is a multicenter, prospective, registry study. by collecting relevant demographic information and clinical data of patients receiving continuous renal replacement therapy (crrt) with pre-mixed solutions, the clinical applicability of pre-mixed solutions will be evaluated in critically ill patients in real-world clinical settings. this study will be carried out in approximately 10 study sites in china. patient data will be collected to evaluate the clinical applicability of pre-mixed solutions.

treatment observation period: from initiation of the first crrt with sponsored pre-mixed solutions to cessation of the pre-mixed solutions. the duration of this period can be up to 10 days. follow-up period: from the cessation of sponsored pre-mixed solutions to day 30 after starting treatment with the pre-mix solutions.

Eligibility criteria:
inclusion criteria: * 18 ≤ age \< 80 years old. * patients admitted to the intensive care unit (icu) and in need of crrt. * patients are willing to receive crrt with at least one of three pre-mixed solutions: regiocit, biphozyl, or prismasol 2. exclusion criteria: * patients with chronic kidney failure who are receiving maintenance dialysis. * patients expected to require the premixed solution for less than 24 hours. * patients who are allergic or have contraindications to components of pre-mixed solutions, as determined by the investigators. * patients who have participated in other interventional studies within the last 30 days. * patients who are pregnant, breastfeeding, or abortus imminence.

Keywords: continuous renal replacement therapy hemofiltration replacement solutions
interest of the ultrasound guidance for the laying of femoral arterial and venous catheters in intensive care unit

Conditions: Severely Traumatized Patients in Emergency Wards

Summary: the femoral approach is the preferred vascular access for the set-up of emergency catheters in severely traumatized patient. this location combines simplicity and speed of installation, it allows the simultaneous set-up of arterial and venous catheters, and is a provider of few complications and failures. the ultrasound guidance has greatly reduced installation times, failures and complications related to the set-up of central venous catheter. this was amply demonstrated in the internal jugular and subclavian site outside of extreme emergency situations (fragou m et al 2011, farrell j et al 1997, karakistos et al 2006). the benefit of ultrasound guidance for the set-up of arterial and venous catheters in the femoral emergency has not been evaluated in terms of reduction in complications. then the main objective of this study is to demonstrate that the ultrasound guidance reduces early complications related to the set-up of arterial and venous catheters in the femoral emergency, among severely traumatized patient compared to the reference anatomical technique.


Eligibility criteria:
inclusion criteria: * adult * included in intensive care unit for severe trauma * need for implementation of femoral arterial and venous catheters in accordance with the practices of the service. * agreed to participate * affiliation to national security exclusion criteria: * contraindication to the set-up of vascular access in femoral position (femoral scarpa wound, aortic dissection) * local infection * hypothermia \<32°c * need for implementation of arterial catheter only * need for implementation of venous catheter only

Keywords: ultrasound guidance emergency wards arterial and venous catheters femoral complications
effectiveness study of psychotherapy in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: psychosomatic is a new approach to understanding the phenomena of somatization using the knowledge of medicine and psychology to treat human being. a brief group psychanalytic psychotherapy (bgpp) for psychosomatic patients has been used to supplement the treatment of some diseases including systemic lupus erythematosus (sle). the hypothesis of the study is that bgpp beside clinical treatment can improve the quality of life and coping in sle patients. the aim of the study is to evaluate the effectiveness of bgpp in brazilian sle patients. primary objective: to evaluate the effectiveness of bgpp to improve quality of life. secondary objectives: to evaluate the effectiveness of bgpp to improve coping, anxiety and depression symptoms. sle patients will be randomized to receive psychotherapy or only clinical treatment. the effectiveness will be assessed through specific questionnaires.

this is a prospective randomized clinical trial. patients with sle (acr criteria, 1997) treated at rheumatology division out-patient clinic of a university hospital were enrolled. a sample of 80 patients was assessed at the beginning of the study (baseline) and will be re-evaluated after 20 weeks (final) by clinical and psychological scales. patients were randomized by computer program and divided into experimental group (eg) and control group (cg). patients of both groups continued their medical treatment at the clinic. eg will be treated with bgpp for 20 sessions once a week for 20 consecutive weeks in small groups. the control group will be on a waiting list until the end of the study and will be treated subsequently. inclusion criteria: * female gender * four or more acr criteria for classification of sle * age above 18 years * follow-up at the clinic for at least 6 months exclusion criteria : * illiterate patients * mental or physical comorbidities that compromise their participation evaluation: the following scales (adapted and validated for portuguese language) were being applied for a blinded evaluator to assess patients at baseline and after 20 weeks: * systemic lupus international disease activity - sledai bombardier,1992); * systemic symptom checklist (ssc)(freire, 2008); * systemic lupus erythematosus quality of life - sleqol (freire, 2008); * coping strategies inventory of folkman and lazarus (savoia,1996). * hospital anxiety and depression (botega, 1995); * vital events scale of holmes and rahe (1967) (savoia, 1995) and comparisons inter and intra groups were being analyzed using the q square test for categorical variables and student's t test, mann-whitney, wilcoxon or anova for quantitative variables. p values \<0.05 will be considered as significant.

Eligibility criteria:
inclusion criteria: * female patients, * sle (acr criteria) * over 18 years old * followed up at the clinic for at least 6 months exclusion criteria: * illiterate patients, * patients with mental or physical comorbidities that compromise their participation

Keywords: systemic lupus erythematosus psychotherapy
feasibility of home telehealth monitoring for improvement in management of hypertension for secondary stroke prevention

Conditions: Stroke; Hypertension

Summary: this research is being done to determine how home blood pressure monitoring, using a commercially available blood pressure monitor with the capability of transmitting readings to stroke doctors can help manage blood pressure in the optimal range after a stroke. high blood pressure is the leading risk factor for stroke. it is important to control high blood pressure after a stroke to prevent another one from happening. we will use the withings smart blood pressure monitor for daily blood pressure measurements. tracking of blood pressure measurements will be done via ipod touch equipped with internet connectivity. we hope to learn if this method of managing blood pressure is more effective than the standard way of having patients visit primary care physicians (the control group for this study). we will also get feedback from participants who will receive the withings smart blood pressure monitor about the ease of use and overall satisfaction with this blood pressure device. people 18-100 years old who have had a stroke in the past 6 months may join. you will be excluded from the study if you are pregnant or plan on becoming pregnant in the near future.


Eligibility criteria:
inclusion criteria: * people 18-100 years old who have had a stroke in the past 6 months may join. exclusion criteria: * you will be excluded from the study if you are pregnant or plan on becoming pregnant in the near future.
usability study of "armassist 2.0." robot: homecare arm rehabilitation in stroke patients

Conditions: Stroke; Rehabilitation; Upper Limb Rehabilitation; Telerehabilitation; Robot-assisted Therapy

Summary: the purpose of this study is to validate the usability of armassist medical device, a robotic system for the rehabilitation of upper limbs in stroke patients (based on serious games). this study evaluate the usability of the system in a home environment, taking into account the ease-to-use, consistency and others; and will pretend demonstrate the feasibility of including or no, robotic therapy in home like complement of daily rehabilitation program. finally this study investigate the acceptance from patients and therapists.


Eligibility criteria:
inclusion criteria: * subjects over 18, * upper limb hemiparesis after stroke, * unilateral paresis and cognitive ability to understand, * accept and actively participate in the usability study. exclusion criteria: * bilateral motor deficit, * severe spasticity, * psychiatric illness, * and/or cognitive impairment.

Keywords: stroke cerebrovascular disorders robotic
internet based self-help for problem gambling concerned significant others

Conditions: Problem Gambling

Summary: the project aims to evaluate a brief online self-help intervention for concerned significant others of individuals with problem gambling. the intervention consists of five modules with texts, films and exercises and is compared to a waiting list.


Eligibility criteria:
inclusion criteria: * no treatment related to the gambling during the past 3 months for the cso * the cso is at least 18 years old * the cso can read and answer questions in swedish. * the cso is assessed as a non-problem gambler according to the gambling disorder identification test. exclusion criteria: * displaying symptoms of severe psychiatric disorders such as psychosis or bipolar disease deemed to needed other treatment options.

Keywords: concerned significant others
study of the association between presbycusis with the incidence of frailty

Conditions: Presbycusis; Frailty Syndrome; Oxidative Stress

Summary: the objective of the project is to establish the association between presbycusis and the incidence of frailty in humans in order to establish hearing loss with age as another index for the diagnosis of frailty; as well as studying the effect of exposure to polyphenols in the diet on presbycusis and frailty. human study: volunteers between 60 and 99 years old, men and women during a period of 6 months, questions and answers, audiometries, study of fragility, analysis of antioxidants in blood, and samples of urine will be measured total polyphenols and oxidant capacity.


Eligibility criteria:
inclusion criteria: * age exclusion criteria: * disease of the hearing system * serious illness (e.g. tumor) * dementia * total dependence
a study of the safety and efficacy of levetiracetam (keppra®) (ucb l059) in children with epilepsy

Conditions: Epilepsy, Partial

Summary: open-label study to allow pediatric patients who have participated in prior levetiracetam (keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until levetiracetam (keppra®) is approved for use in children or until the completion of the development program for pediatrics.


Eligibility criteria:
inclusion criteria: * have completed study n151, or any other applicable pediatric trials of levetiracetam (keppra®) * be a patient for whom the treatment of levetiracetam (keppra®) would be of potential benefit such that the patient/parent(s)/legal guardian and the investigator agree to continue treatment. exclusion criteria: * not be on a ketogenic diet (during the course of this study). * not have seizures too close together to accurately count (i.e., the patient's seizures must be countable).

Keywords: epilepsy pediatric partial onset epilepsy levetiracetam keppra
fatty acid supplementation in children with asd

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is to examine how fatty acid supplementation alters biological signatures in children with asd

children with autism spectrum disorder (asd) suffer from both mental and physical symptoms that affect their quality of life and severely disrupt family well-being. fatty acid supplements are natural products with anti-inflammatory properties often used for treatment of asd symptoms, but their efficacy remains unproven. the objective of the proposed protocol is to quantify the impact of omega 3-6 on pre-specified biological signatures. the hypotheses were formulated based on data from the investigators previous studies and other published data which suggest that the inflammatory markers, il-1β, il-2, and ifnγ are consistently elevated in children with asd and decreases in these markers correlate with asd symptom improvement. the investigators long-term goal is to identify effective treatments for asd.

Eligibility criteria:
inclusion criteria: * age 2-6 years old * asd diagnosis at nationwide children's hospital within the prior 6 months * ados-2 score in "autism" (severe) range * english is primary language exclusion criteria: * fatty acid supplementation in the past 6 months * consumes fatty fish more than 3 times per week * still breastfeeding or formula feeding * quadriparesis * deafness * blindness * seizure disorder diagnosis * autoimmune disorder including type 1 diabetes, fragile x, rett, angleman syndromes, tuberous schlerosis * feeding problems precluding consumption of the supplement * ingredient allergy (canola, fish, or borage seed) * planned surgeries scheduled within the time frame of trial participation
ultrasound beams as an adjunct to reperfusion therapy in stemi

Conditions: Myocardial Infarction; ST Elevation Myocardial Infarction

Summary: successfully perfused stemi patients will receive routine transthoracic echocardiography qid for 4 days or placebo. myocardial function and infarct size will be evaluated at 3 and 6 months.

patients who had acute stemi and successfully reperfused by either thrombolytic therapy or primary angioplasty and stenting will be included this study. a basal routine echocardiography will be obtained in all patients after reperfusion therapy. thereafter, patients will be divided into two groups: 1.treatment group will receive transthoracic echocardiography using philips hd11 xe ® for 30 minutes qid for 4 days. 2. placebo group will have the same philips hd11 xe ® echo transducer applied for the same time and duration on their chest but with the ultrasound turned-off. detailed left and right ventricle function as well as performance index and stress-strain imaging will be obtained and analyzed at 3 and 6 months.

Eligibility criteria:
inclusion criteria: -patients presenting within 12 hours of their first st- elevation myocardial infarction that is successfully reperfused; and completed baseline echocardiographic evaluation and accepted participation in the study exclusion criteria: patients: * with prior st- elevation myocardial infarction * patients presenting \>12hrs * not successfully reperfused * not completed baseline echo evaluation, * not accepting participation in the study

Keywords: c14.280.647.500